A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3201 Tablets in Patients With Advanced Prostate Cancer
Latest Information Update: 18 Sep 2025
At a glance
- Drugs Antineoplastics (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 18 Sep 2025 New trial record
- 17 Sep 2025 New source identified and integrated (China Drug Trials;CTR20253637)